Journal article
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors
Cancer chemotherapy and pharmacology, Vol.64(1), pp.79-86
06/01/2009
DOI: 10.1007/s00280-008-0845-0
PMCID: PMC3043989
PMID: 18941749
Abstract
The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP.
Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA).
Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 +/- A 0.94 SD, vs 0.41 +/- A 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 +/- A 1.49 SD, vs 0.29 +/- A 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12).
RRM2 gene and protein expression varies by tumor type.
Details
- Title: Subtitle
- Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors
- Creators
- Jill Kolesar - University of Wisconsin Carbone Cancer CenterWei Huang - University of Wisconsin Carbone Cancer CenterJens Eickhoff - University of Wisconsin Carbone Cancer CenterKristine Hahn - University of Wisconsin Carbone Cancer CenterDona Alberti - University of Wisconsin Carbone Cancer CenterSteven Attia - University of Wisconsin Carbone Cancer CenterWilliam Schelman - University of Wisconsin Carbone Cancer CenterKyle Holen - University of Wisconsin Carbone Cancer CenterAnne Traynor - University of Wisconsin–MadisonPercy Ivy - National Cancer InstituteGeorge Wilding - University of Wisconsin Carbone Cancer Center
- Resource Type
- Journal article
- Publication Details
- Cancer chemotherapy and pharmacology, Vol.64(1), pp.79-86
- DOI
- 10.1007/s00280-008-0845-0
- PMID
- 18941749
- PMCID
- PMC3043989
- NLM abbreviation
- Cancer Chemother Pharmacol
- ISSN
- 0344-5704
- eISSN
- 1432-0843
- Publisher
- Springer Nature
- Number of pages
- 8
- Grant note
- 24XS090; 1ULRR025011 / NCI; CTEP Translational Research Initiative Funding; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) National Center for Research Resources; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Research Resources (NCRR) U01CA062491 / Early Clinical Trials of Anti-Cancer Agents with Phase I Emphasis Physician Scientist Training in Cancer Medicine U01CA062491 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) UL1RR025011 / NATIONAL CENTER FOR RESEARCH RESOURCES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Research Resources (NCRR) T32 CA009614 / NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
- Language
- English
- Date published
- 06/01/2009
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984696552802771
Metrics
5 Record Views